Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

161. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab (...) : a systematic literature review and meta-analysis of randomized controlled trials Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ CRD summary High-dose tocilizumab in combination with methotrexate as a treatment for rheumatoid arthritis was associated with a small but significant increase in adverse events and infection compared to controls; the effect was unclear for tocilizumab monotherapy. Limitations in study numbers and the review process mean that the results should be treated with caution. Authors

DARE.2011

162. Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis

Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Smits NA, Duru N, Bijlsma JW, Jacobs JW CRD summary The review concluded that intravenous glucocorticoid pulse therapy resulted in a high adverse event rate; cardiovascular adverse events were (...) the most commonly reported. The review had methodological and data limitations that limit the reliability of the authors’ conclusions. Authors' objectives To determine the adverse events associated with intravenous pulse glucocorticoids for inflammatory diseases. Searching PubMed, EMBASE and The Cochrane Library were searched to October 2009 for articles published in English. Full search strategies were reported. Reference lists of retrieved studies were searched. Study selection Full text randomised

DARE.2011

163. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after (...) percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S CRD summary Routine early tirofiban use plus aspirin and clopidogrel in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention may have reduced major adverse cardiovascular events without increasing major bleeding rates. The conclusions were not definitive due to limited

DARE.2011

164. Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel | Evidence-Based Medicine This site uses cookies (...) with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Article Text Prognosis Systematic review Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Andrea H Ramirez 1 , Jessica T Delaney 1 , Alan R Shuldiner 2 Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2011

165. Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events ? new restrictions and monitoring requirements

Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events ? new restrictions and monitoring requirements Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements From: Published: 13 October 2011 Therapeutic area (...) (Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy) had been investigating the potential clinical benefit of dronedarone (added to standard therapy) in patients older than 65 years with permanent atrial fibrillation in the reduction of: major cardiovascular (CV) events (ie, stroke, systemic arterial embolism, myocardial infarction, or cardiovascular death) unplanned cardiovascular hospitalisation or death from any cause The study was prematurely terminated in July

MHRA Drug Safety Update2011

166. Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events

Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events Enzira/CSL Biotherapies and Viroflu/Inflexal V influenza vaccines and risk of febrile reactions in children under 5 years Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Enzira/CSL Biotherapies and Viroflu/Inflexal V influenza vaccines and risk of febrile reactions in children under 5 years From: Published: 13 October 2011 Therapeutic area: Use alternative vaccines in under 5s and report (...) suspected adverse reactions Article date: October 2011 Prescribers are reminded that Enzira and CSL Biotherapies generic influenza vaccines (both manufactured by CSL and marketed by Pfizer) should not be given to children younger than 5 years. These vaccines are not authorised for use in this age-group after the increased risk of febrile convulsions observed in Australia last year (see ). CSL also supplies starting materials for the manufacture of another flu vaccine, Viroflu and Inflexal V (both

MHRA Drug Safety Update2011

167. Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta?analysis

Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta?analysis RxFiles Trial Summary Q&A www.RxFiles.ca - July 2011 Could the NNH really be 28? Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta-analysis 1 Findings at a glance In 14 randomized placebo controlled trials with 8216 participants, varenicline was associated with an increase in serious adverse CV events. o (...) . ? In 14 trials that analysed 8216 patients on varenicline vs placebo, the NNH was 417. In 0 trials analysing 0 patients, but all of whom were at much higher risk, this extrapolated NNH would be 28, assuming that the proposed odds ratio holds true. Note that the absolute risk of continuing smoking would also be a major factor to consider in weighing the risk/benefit of therapy. Extras: RxFiles Meta Q&A – July 2011: Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix, Chantix

RxFiles2011

168. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB 20627913 2010 07 14 2010 08 05 2013 11 21 1468-3296 65 7 2010 Jul Thorax Thorax Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. 582-7 10.1136/thx.2009.125054 Treatment for latent tuberculosis infection with isoniazid (...) for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events. To compare the health system costs of 4RIF and 9INH. In a randomised trial conducted in five Canadian centres, one Brazilian and one Saudi Arabian centre, consenting subjects were randomised to receive 4RIF or 9INH. Health system costs were estimated from healthcare utilisation including scheduled and unscheduled

EvidenceUpdates2010

169. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study

Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study 19581281 2010 05 25 2010 07 16 2016 11 25 1468-2060 69 6 2010 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. 1044-8 10.1136/ard.2008.106617 To evaluate toxicity (...) profiles in patients with rheumatoid arthritis (RA) treated either according to an intensive or a conventional treatment strategy approach with methotrexate (MTX) and to study factors associated with MTX-related toxicity. Data were used from the Computer-Assisted Management in Early Rheumatoid Arthritis (CAMERA) study, in which clinical efficacy of an intensive treatment strategy with MTX was more beneficial than a conventional treatment strategy approach. In this study, data on adverse events (AEs

EvidenceUpdates2010

170. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up

A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up 19778920 2010 04 28 2010 06 08 2014 03 10 1468-201X 96 9 2010 May Heart (British Cardiac Society) Heart A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. 662-7 10.1136/hrt.2009.177162 Few reports described (...) . Before the first angioplasty patients were randomly assigned to three different strategies: culprit vessel angioplasty-only (COR group); staged revascularisation (SR group) and simultaneous treatment of non-IRA (CR group). During a mean follow-up of 2.5 years, 42 (50.0%) patients in the COR group experienced at least one major adverse cardiac event (MACE), 13 (20.0%) in the SR group and 15 (23.1%) in the CR group, p<0.001. Inhospital death, repeat revascularisation and re-hospitalisation occurred

EvidenceUpdates2010

171. Use of manometry for laryngeal mask airway reduces postoperative pharyngolaryngeal adverse events: a prospective, randomized trial

Use of manometry for laryngeal mask airway reduces postoperative pharyngolaryngeal adverse events: a prospective, randomized trial 20179502 2010 02 24 2010 03 30 2015 11 19 1528-1175 112 3 2010 Mar Anesthesiology Anesthesiology Use of manometry for laryngeal mask airway reduces postoperative pharyngolaryngeal adverse events: a prospective, randomized trial. 652-7 10.1097/ALN.0b013e3181cf4346 Adverse events such as pharyngolaryngeal complications are indicators of quality patient care. Use (...) Journal Article Randomized Controlled Trial United States Anesthesiology 1300217 0003-3022 AIM IM Adolescent Adult Aged Aged, 80 and over Ambulatory Surgical Procedures Anesthesia, Inhalation Anesthesia, Intravenous Deglutition Disorders etiology prevention & control Dysphonia etiology prevention & control Female Humans Intubation, Intratracheal adverse effects methods Laryngeal Masks Larynx injuries Male Manometry methods Middle Aged Monitoring, Intraoperative Pharyngitis etiology prevention

EvidenceUpdates2010

172. Associations between renal duplex parameters and adverse cardiovascular events in the elderly: a prospective cohort study

Associations between renal duplex parameters and adverse cardiovascular events in the elderly: a prospective cohort study 20116688 2010 02 01 2010 02 22 2016 12 03 1523-6838 55 2 2010 Feb American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Associations between renal duplex parameters and adverse cardiovascular events in the elderly: a prospective cohort study. 281-90 10.1053/j.ajkd.2009.10.044 Atherosclerotic renovascular disease (...) is associated with an increased risk of cardiovascular disease (CVD) events. This study examines associations between Doppler-derived parameters from the renal artery and renal parenchyma and all-cause mortality and fatal and nonfatal CVD events in a cohort of elderly Americans. Cohort study. A subset of participants from the Cardiovascular Health Study (CHS). Through an ancillary study, 870 (70% recruitment) Forsyth County, NC, CHS participants consented to undergo renal duplex sonography to define

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

173. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study 20039804 2010 01 11 2010 01 27 2010 01 11 1537-6613 201 3 2010 Feb 01 The Journal of infectious diseases J. Infect. Dis. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection (...) on adverse events of anti-HIV drugs (D:A:D) study. 318-30 10.1086/649897 BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per

EvidenceUpdates2010

175. Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents

Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents Khawaja OA, Shaikh KA, Al-Mallah MH CRD summary This review found that evidence suggested that use of contrast agents with echocardiography was safe and not associated with an increase in incidence (...) affected the review, although serious adverse event reporting was more likely to have been published. The methods of data extraction were aimed at reducing reviewer error or bias; study selection methods were not described. The authors did not appear to assess study quality, so it was difficult to comment on the validity of included data. Tests showed considerable heterogeneity between studies and it may not have been appropriate to combine data, although all studies individually showed no increased

DARE.2010

176. Anhedonia predicts adverse cardiac events in people with acute coronary syndromes

Anhedonia predicts adverse cardiac events in people with acute coronary syndromes Anhedonia predicts adverse cardiac events in people with acute coronary syndromes | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Anhedonia predicts adverse cardiac events in people with acute coronary syndromes Article Text Prognosis Anhedonia predicts adverse cardiac events in people with acute coronary syndromes Statistics from Altmetric.com No Altmetric data available for this article. Question Question Does anhedonia and/or depressed mood predict recurrent

Evidence-Based Mental Health2010

177. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals

Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta (...) -analysis of one hundred and twenty studies involving 177,390 individuals Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO CRD summary The authors concluded that nicotine replacement therapy for smoking cessation was associated with various side-effects and, in addition to counselling and medical monitoring, clinicians should inform patients of potential side effects. Problems differentiating adverse events due to smoking cessation from those associated with nicotine replacement therapy treatment mean

DARE.2010

178. Systematic review: Adding atypical antipsychotics to antidepressants increases response in treatment-resistant major depression but increases discontinuation as a result of adverse events

Systematic review: Adding atypical antipsychotics to antidepressants increases response in treatment-resistant major depression but increases discontinuation as a result of adverse events Adding atypical antipsychotics to antidepressants increases response in treatment-resistant major depression but increases discontinuation as a result of adverse events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your (...) of adverse events Article Text Therapeutics Systematic review Adding atypical antipsychotics to antidepressants increases response in treatment-resistant major depression but increases discontinuation as a result of adverse events Gabor I Keitner Gabor I Keitner Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA; GKeitner{at}Lifespan.org Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Nelson JC

Evidence-Based Medicine (Requires free registration)2010

179. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain

Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain Langley PC, Patkar AD, Boswell KA, Benson CJ, Schein JR CRD summary This review assessed the safety of long-acting formulations of tramadol hydrochloride in the treatment of chronic osteoarthritis pain and concluded (...) that differences in formulations may influence rates of adverse events. However, these differences should be interpreted with caution. Potential bias in the review, heterogeneity among studies and their unclear quality, support the authors' recommendation to interpret the findings with caution. Authors' objectives To assess the safety of various long-acting formulations of tramadol hydrochloride in the treatment of chronic osteoarthritis pain. Searching MEDLINE and EMBASE were searched between 1997 and 2008

DARE.2010

180. Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease

Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major (...) adverse cardiac events in patients with coronary artery disease Hao PP, Chen YG, Wang JL, Ji WQ, Xue L, Liu XH, Wang XL, Zhang Y CRD summary The review found that high-dose statin therapy administered prior to percutaneous coronary intervention compared to placebo was effective for prevention of major adverse cardiac events in patients with coronary artery disease. The authors' conclusion reflected the evidence and was appropriate, but should be interpreted cautiously due to potential for missing

DARE.2010